MYGN Research and Charts

MYGN - Myriad Genetics Inc (Healthcare: Diagnostics & Research)

Projected Earnings Date: 2025-02-06 (Delayed quote data 2025-01-03)

Last 13.67	Change ⇑ +0.17 (+1.26%)	Volume 830,534
	Open 13.50	High 13.94	Low 13.40

8EMA (Daily) 13.64	40EMA (Daily) 15.74	50EMA (Daily) 16.52	STO (Daily) 29.593	MACD Hist (Daily) 0.326
8EMA (Weekly) 15.209	40EMA (Weekly) 20.50	50EMA (Weekly) 20.78	STO (Weekly) 4.146	MACD Hist (Weekly) -1.630


Company Profile
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual?s risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.